Create Account
Log In
Dark
chart
exchange
Premium
Terminal
Screener
Stocks
Crypto
Forex
Trends
Depth
Close
Check out our API

SLP
Simulations Plus, Inc.
stock NASDAQ

At Close
Dec 12, 2025 3:59:34 PM EST
19.20USD-1.589%(-0.31)419,601
19.18Bid   19.20Ask   0.02Spread
Pre-market
Dec 9, 2025 8:26:30 AM EST
20.69USD+6.048%(+1.18)0
After-hours
Dec 12, 2025 4:00:30 PM EST
19.17USD-0.156%(-0.03)212
OverviewOption ChainMax PainOptionsPrice & VolumeSplitsDividendsHistoricalExchange VolumeDark Pool LevelsDark Pool PrintsExchangesShort VolumeShort Interest - DailyShort InterestBorrow Fee (CTB)Failure to Deliver (FTD)ShortsTrendsNewsNews
Jan 20, 2022
08:36AM EST  Simulations Plus Partners With Large Pharmaceutical Company To Drive Advancements To GastroPlus Mechanistic Oral Absorption Model   Benzinga
Jan 13, 2022
11:47AM EST  Simulations Plus Announces Collaboration With An Animal Health Company   Benzinga
Jan 6, 2022
04:17PM EST  Simulations Plus: Q1 Earnings Insights   Benzinga
04:14PM EST  Simulations Plus Q1 Sales $12.42M Beat $11.28M Estimate   Benzinga
04:14AM EST  Earnings Scheduled For January 6, 2022   Benzinga
Dec 2, 2021
08:33AM EST  Simulations Plus Extends Its Distributor Agreement In Japan With Northern Science Consulting For Monolix   Benzinga
Nov 30, 2021
10:00AM EST  Simulations Plus celebrates 25-year anniversary with $25,000 gift to nonprofit   PR Newswire
Oct 26, 2021
10:08AM EDT  Benzinga's Top Ratings Upgrades, Downgrades For October 26, 2021   Benzinga
09:09AM EDT  Craig-Hallum Upgrades Simulations Plus to Buy, Lowers Price Target to $53   Benzinga
08:33AM EDT  Simulations Plus And University Of Connecticut Awarded New FDA Contract To Accelerate Development Of Long-Acting Injectable Products; Size Not Disclosed   Benzinga
Oct 25, 2021
02:20PM EDT  Simulations Plus Sees FY21 Revs $51M-$53M Vs $44.8M Est   Benzinga
02:16PM EDT  Simulations Plus Q4 EPS $0.01 Misses $0.05 Estimate, Sales $9.80M Beat $8.17M Estimate   Benzinga
04:24AM EDT  Earnings Scheduled For October 25, 2021   Benzinga
Sep 23, 2021
08:42AM EDT  Simulations Plus Receives New Grant Award From FDA For $250K/Year   Benzinga
Aug 19, 2021
08:43AM EDT  Simulations Plus Reports Received Second Phase Of Experimental Results From Collaborative Research Deal With A Large Pharma Co. To Evaluate Impact Of New AI-Driven Drug Design Module In ADMET Predictor   Benzinga
Aug 4, 2021
09:20AM EDT  Simulations Plus Earlier Announced Receipt Of An Order From The Center For Drug Evaluation Of The National Medical Products Administration To Add Licenses To GastroPlus   Benzinga
Jul 29, 2021
02:25PM EDT  Return on Capital Employed Overview: Simulations Plus   Benzinga
Jul 23, 2021
11:10AM EDT  Looking into Simulations Plus's Return on Capital Employed   Benzinga
Jul 22, 2021
10:56AM EDT  Analyzing Simulations Plus's Ex-Dividend Date   Benzinga
Jul 13, 2021
02:00PM EDT  Simulations Plus Target Price Lowered At Craig-Hallum, Raymond James After Q3 Sales Miss Expectations   Benzinga
07:55AM EDT  Raymond James Maintains Outperform on Simulations Plus, Lowers Price Target to $54   Benzinga
Jul 12, 2021
04:27PM EDT  Simulations Plus: Q3 Earnings Insights   Benzinga
04:06PM EDT  Simulations Plus Q3 EPS $0.18, Inline, Sales $12.80M Miss $14.74M Estimate   Benzinga
06:11AM EDT  A Peek Into The Markets: US Stock Futures Mostly Lower; Crude Oil Down   Benzinga
04:00AM EDT  Earnings Scheduled For July 12, 2021   Benzinga
Jul 9, 2021
10:31AM EDT  Simulations Plus Earnings Preview   Benzinga
May 12, 2021
08:44AM EDT  Simulations Plus Says Uplisted To Nasdaq Global Select Market   Benzinga
08:40AM EDT  Simulations Plus Uplisted To The Nasdaq Global Select Market   Benzinga
Apr 27, 2021
08:30AM EDT  Simulations Plus Releases ADMET Predictor(r) (X.2)   Business Wire
Apr 22, 2021
10:21AM EDT  Understanding Simulations Plus's Ex-Dividend Date   Benzinga
Apr 20, 2021
08:38AM EDT  Simulations Plus Says FDA Renews Licenses Of DILIsym Software   RTTNews
08:37AM EDT  Simulations Plus Says U.S. FDA Renews Licenses of DILIsym Software   Benzinga
08:31AM EDT  Simulations Plus Announces FDA Renews Licenses Of Co.'s DILIsym Software   Benzinga
08:30AM EDT  U.S. FDA Renews Licenses of DILIsym Software   Business Wire
Apr 13, 2021
06:16AM EDT  A Peek Into The Markets: US Stock Futures Edge Higher; Inflation Data In Focus   Benzinga
Apr 12, 2021
04:16PM EDT  Simulations Plus: Q2 Earnings Insights   Benzinga
04:08PM EDT  Simulations Plus Q2 EPS $0.15 Beats $0.14 Estimate, Sales $13.10M Beat $12.84M Estimate   Benzinga
04:36AM EDT  Earnings Scheduled For April 12, 2021   Benzinga
Apr 9, 2021
11:39AM EDT  Simulations Plus's Earnings: A Preview   Benzinga
Apr 7, 2021
08:36AM EDT  Simulations Plus Reports Successful Results From AIDD Collaboration With 'Large Pharmaceutical Company'   Benzinga
Feb 2, 2021
08:40AM EST  Simulations Plus Enters Agreement With Distributor In China   Benzinga
Jan 12, 2021
10:35AM EST  Craig-Hallum Downgrades Simulations Plus to Hold   Benzinga
08:33AM EST  Simulations Plus Enters New Funded Collaboration to Improve Lung Exposure Models For Pulmonary Infection Treatments   Benzinga
Jan 11, 2021
05:11PM EST  Recap: Simulations Plus Q1 Earnings   Benzinga
04:06PM EST  Simulations Plus Q1 EPS $0.12 Beats $0.11 Estimate, Sales $10.70M Beat $10.64M Estimate   Benzinga
04:04AM EST  Earnings Scheduled For January 11, 2021   Benzinga
Jan 8, 2021
10:08AM EST  Earnings Outlook For Simulations Plus   Benzinga
Jan 5, 2021
08:31AM EST  Simulations Plus Reports New Funded Collaboration To Enhance GastroPlus ACAT Model For Oral Absorption Of Peptides   Benzinga
Dec 1, 2020
04:08PM EST  Simulations Plus Names Will Frederick As CFO   Benzinga
Nov 16, 2020
04:53PM EST  Recap: Simulations Plus Q4 Earnings   Benzinga
04:17PM EST  Simulations Plus Q4 Adj. EPS $0.11 Beats $0.09 Estimate, Sales $9.54M Beat $9.38M Estimate   Benzinga
04:26AM EST  Earnings Scheduled For November 16, 2020   Benzinga
Oct 27, 2020
08:35AM EDT  First Approved Cancer Treatment For TGCT Included DILIsym Simulations In FDA Review   Benzinga
Oct 16, 2020
09:40AM EDT  Benzinga's Top Upgrades, Downgrades For October 16, 2020   Benzinga
07:24AM EDT  Raymond James Initiates Coverage On Simulations Plus with Outperform Rating, Announces Price Target of $95   Benzinga
Sep 29, 2020
08:45AM EDT  Simulations Plus Extends Partnership With Large Pharmaceutical Company To Further Expand High-Throughput PBPK Capabilities In ADMET Predictor   Benzinga
Sep 22, 2020
08:33AM EDT  Simulations Plus Reports Partnership With A Large Pharma Co. To Evaluate New AIDD Module In Recently-Launched Version Of ADMET Predictor, No Terms Disclosed   Benzinga
Sep 15, 2020
08:48AM EDT  Simulations Plus Releases ADMET Predictor Version 10.0 (APX)   Benzinga
Sep 8, 2020
11:39AM EDT  Oppenheimer Initiates Coverage On Simulations Plus with Outperform Rating, Announces Price Target of $79   Benzinga
Sep 2, 2020
08:36AM EDT  Simulations Plus Subsidiary DILIsym Services Highlight's FDA's Use Of Co's Software In Simulations   Benzinga
Aug 4, 2020
07:22AM EDT  Simulations Plus Reports Proposed Common Stock Offering, No Size Disclosed   Benzinga


Share
About
Pricing
Policies
Markets
API
Info
tz UTC-5
Connect with us
ChartExchange Email
ChartExchange on Discord
ChartExchange on X
ChartExchange on Reddit
ChartExchange on GitHub
ChartExchange on YouTube
© 2020 - 2025 ChartExchange LLC